Document is current
Any future updates will be listed below
-
Authors
Abramson, Alex https://orcid.org/0000-0003-4876-9751
Caffarel-Salvador, Ester https://orcid.org/0000-0002-2844-7598
Soares, Vance
Minahan, Daniel https://orcid.org/0000-0003-3065-055X
Tian, Ryan Yu
Lu, Xiaoya
Dellal, David
Gao, Yuan
Kim, Soyoung
Wainer, Jacob
Collins, Joy
Tamang, Siddartha
Hayward, Alison
Yoshitake, Tadayuki
Lee, Hsiang-Chieh
Fujimoto, James https://orcid.org/0000-0002-0828-4357
Fels, Johannes https://orcid.org/0000-0002-6616-6746
Frederiksen, Morten Revsgaard https://orcid.org/0000-0003-0000-4426
Rahbek, Ulrik
Roxhed, Niclas
Langer, Robert https://orcid.org/0000-0003-4255-0492
Traverso, Giovanni https://orcid.org/0000-0001-7851-4077
-
Funding
Funding for this research was provided by:
Novo Nordisk
Department of mechanical engineering, MIT Brigham and woman's hospital division of gastroenterology
National Science Foundation
MIT undergraduate research opportunities program
Foundation for the National Institutes of Health (R01-CA075289-21, R01-CA075289-21, R01-CA075289-21, EB-00244)
Olof Viking Bjork scholarship trust
- License Information
-
More Information
Article History
Received: 20 December 2018
Accepted: 28 August 2019
First Online: 7 October 2019
Competing interests
: A.A., E.C.-S., D.D., N.R., M.R.F., Y.G., R.L. and G.T. are co-inventors on multiple patent applications describing oral biologic drug delivery. J. Fels, M.R.F. and U.R. work for Novo Nordisk. A.A., R.L. and G.T. report having received consulting fees from Novo Nordisk. A.A. reports having received consulting fees from Eli Lilly. Complete details of all relationships for profit and not for profit for G.T. can found at . For a list of entities with which R.L. is involved (compensated or uncompensated), see .
